Business Context and Reporting Period
This Form 8-K was filed by Akebia Therapeutics, Inc. on September 22, 2021. The report details a settlement and license agreement entered into by Keryx Biopharmaceuticals, Inc., a wholly owned subsidiary of Akebia, along with its licensors Panion & BF Biotech, Inc. and Dr. Chen Hsing Hsu.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a legal settlement regarding intellectual property rights.
Material Changes and Events
- Settlement Agreement: A settlement was reached with Mylan Pharmaceuticals Inc. to resolve patent litigation concerning Mylan's Abbreviated New Drug Application (ANDA) for a generic version of Auryxia (ferric citrate).
- License Grant: Keryx, Panion, and Dr. Hsu granted Mylan a license to market a generic version of Auryxia in the United States beginning on March 20, 2025, subject to FDA approval or earlier under customary circumstances.
- Litigation Termination: All ongoing litigation regarding Auryxia patents between the parties in the U.S. District Court for the District of Delaware and the North District Court of West Virginia will be terminated.
- Regulatory Review: The agreement is confidential and subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.
Guidance, Outlook, and Risks
The filing indicates that Keryx, Panion, and Dr. Hsu have now entered into settlement agreements resolving all patent litigation proceedings brought in response to ANDAs filed by third parties seeking to market generic versions of Auryxia prior to patent expiration. No specific financial guidance or management commentary regarding future earnings is provided in this text.
Investor Verification Checklist
- Verify the exact terms of the settlement agreement, noting that the document states the agreement is confidential.
- Confirm the status of the U.S. Federal Trade Commission and Department of Justice review of the agreement.
- Monitor FDA approval timelines for Mylan's generic Auryxia to determine if the March 20, 2025 launch date is met or accelerated.
- Review the impact of this settlement on the remaining patent exclusivity period for Auryxia compared to prior settlements with Teva, Watson, Par, Lupin, and Chemo Research.